These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence. Rahaghi FF; Miravitlles M Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837 [TBL] [Abstract][Full Text] [Related]
13. The role of augmentation therapy in alpha-1 antitrypsin deficiency. Kueppers F Curr Med Res Opin; 2011 Mar; 27(3):579-88. PubMed ID: 21226542 [TBL] [Abstract][Full Text] [Related]
14. Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis. Barjaktarevic I; Miravitlles M BMC Pulm Med; 2021 Mar; 21(1):99. PubMed ID: 33757485 [TBL] [Abstract][Full Text] [Related]
15. Consequences of Abrupt Cessation of Alpha McElvaney OJ; Carroll TP; Franciosi AN; Sweeney J; Hobbs BD; Kowlessar V; Gunaratnam C; Reeves EP; McElvaney NG N Engl J Med; 2020 Apr; 382(15):1478-1480. PubMed ID: 32268034 [No Abstract] [Full Text] [Related]
16. Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand. Dummer J; Dobler CC; Holmes M; Chambers D; Yang IA; Parkin L; Smith S; Wark P; Dev A; Hodge S; Dabscheck E; Gooi J; Samuel S; Knowles S; Holland AE Respirology; 2020 Mar; 25(3):321-335. PubMed ID: 32030868 [TBL] [Abstract][Full Text] [Related]
18. Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis. Campos MA; Runken MC; Davis AM; Johnson MP; Stone GA; Buikema AR Adv Ther; 2018 Apr; 35(4):467-481. PubMed ID: 29616482 [TBL] [Abstract][Full Text] [Related]